Contribution of Immuno - PET préciblée the bispecific antibody with anti- CEA x anti -HSG peptide IMP and TF2 -288 labeled with Gallium -68 For Imaging of Patients Potentially Candidates An excisional surgery and / or thermoablation One or several of local metastases at diagnosis or relapse When Colo- rectal Cancers (CCR) Expressing Carcino antigen ( CEA) : Comparison with Conventional Review [Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel]

Trial Profile

Contribution of Immuno - PET préciblée the bispecific antibody with anti- CEA x anti -HSG peptide IMP and TF2 -288 labeled with Gallium -68 For Imaging of Patients Potentially Candidates An excisional surgery and / or thermoablation One or several of local metastases at diagnosis or relapse When Colo- rectal Cancers (CCR) Expressing Carcino antigen ( CEA) : Comparison with Conventional Review [Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
  • Indications Colorectal cancer
  • Focus Diagnostic use
  • Acronyms iTEP Colon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jan 2017 Status changed from recruiting to completed.
    • 24 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top